Since 1993, the AACR has awarded more than $540 million in grants to fund meritorious research projects across the spectrum of cancer science, including basic, translational, and clinical research. See how the AACR grants program has contributed to the AACR's mission.
After undergraduate education at Harvard University, Ravi Majeti earned his MD and PhD at University of California San Francisco. He took an interest in acute myeloid leukemia (AML) in medical school and cared for patients with AML during his residency in internal medicine at Brigham and Women’s Hospital in Boston and Hematology fellowship at Stanford University...
Lung cancer remains the number one cause of cancer-related death. This persistent dismal prognosis has been largely attributed to late-stage diagnosis, when 5-year survival rates are less than 5%. Although the potential of lung cancer screening to reduce lung cancer-related mortality has been demonstrated, there remains a need for more effective and less invasive early detection methods. The AACR-Johnson & Johnson Lung Cancer Innovative Science Grants are fueling...
Despite demonstrated success in many solid tumor types, immune checkpoint blockade (ICB) agents have minimal efficacy in high grade serous ovarian cancer (HGSC). In this study, the authors describe a novel bispecific anti-PD-1/PD-L1 antibody, which showed increased anti-tumor efficacy compared to mono-specific anti-PD-1 or anti-PDL1. The researchers also...
In 2019, Michael D. Story, PhD, was one of the inaugural recipients of the AACR-Novocure Tumor Treating Fields (TTFields) Research Grants Program. Now in 2020, he has the pleasure of seeing his mentee, Narasimha Kumar Karanam, PhD, receive an AACR-Novocure Career Development Award for Tumor Treating Fields Research.
Dr. Channing Der serves as the Sarah Graham Kenan Professor of Pharmacology at the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill. Having received his PhD from the University of California at Irvine, Dr. Der went on to complete his postdoctoral research training at the Dana-Farber Cancer Institute and Harvard Medical School. As a two-time PanCAN-AACR grant recipient...
AACR has been the Scientific Partner of Stand Up To Cancer (SU2C) since 2008. It supports the scientific oversight, expert peer review and administration of many SU2C-funded grants. To keep the scientific community informed of the impact of this scientific partnership, a subset of research articles published by SU2C-funded scientists are summarized.
For Michael Jensen, MD, a grant from the AACR came at a good time. It was 1996, and Jensen was at the Fred Hutchinson Cancer Research Center in Seattle for his fellowship as a pediatric oncologist-hematologist, working in the laboratory of....
The AACR is committed to help mitigate the disproportionate burden of cancer on certain segments of the population. As a cornerstone of its educational and advocacy efforts, the AACR recently released the inaugural AACR Cancer Disparities Progress Report. A complementary strategy...
Dr. Sonia del Rincón and the Stand Up to Cancer (SU2C) Canada Metastatic Breast Cancer Dream Team are looking to understand the impact of MAP kinase–interacting serine/threonine kinases 1 and 2 (MNK1/2) inhibitors on metastatic breast cancer...
Pancreatic cancer is forecasted to become the 2nd deadliest cancer in the United States by 2030. The AACR, in partnership with the Lustgarten Foundation and Pancreatic Cancer Action Network (PanCAN), brought together top scientists in the AACR Special Conference...